Abstract Staphylococcal enterotoxins A (SEA) and B (SEB) are classical models of superantigens (SAg), which induce potent T-cell-stimulating activity by forming complexes with MHC class II molecules on antigen-presenting cells. This large-scale activation of T-cells is accompanied by increased production of cytokines such as interferon-(IFN-). Additionally, as we previously reported, IFN--producing CD8 + T cells act as "helper cells," supporting the ability of dendritic cells to produce interleukin-12 (IL-12)p70. Here, we show that DC pulsed with SAg promote the enhancement of anti-tumor immunity. Murine bone marrow-derived dendritic cells (DC) were pulsed with OVA 257-264 (SIINFEKL), which is an H-2Kb target epitope of EG7 [ovalbumin (OVA)-expressing EL4] cell lines, in the presence of SEA and SEB and were subcutaneously injected into naïve C57BL/6 mice. SAg plus OVA 257-264 -pulsed DC vaccine strongly enhanced peptide-speciWc CD8 + T cells exhibiting OVA 257-264 -speciWc cytotoxic activity and IFN-production, leading to the induction of protective immunity against EG7 tumors. Furthermore, cyclophosphamide (CY) added to SAg plus tumor-antigens (OVA 257-264 , tumor lysate, or TRP-2) pulsed DC immunization markedly enhanced tumor-speciWc T-cell expansion and had a signiWcant therapeutic eVect against various tumors (EG7, 2LL, and B16). Superantigens are potential candidates for enhancing tumor immunity in DC vaccines.
Introduction
Staphylococcal enterotoxins A (SEA) and B (SEB) are classical models of bacterial superantigens (SAg). Unlike conventional antigens, SAg bind directly to the lateral surfaces of MHC class II molecules and to the V domain of the TCR; therefore, they do not need to be processed and presented like conventional antigens [1] [2] [3] [4] . This ability enables SAg to induce large-scale activation of the immune system by stimulating the large number of T-cells that express -chains of the T-cell antigen receptor, which contain variable regions coded for by speciWc families of V genes. Furthermore, this large-scale activation of T-cells is accompanied by the increased production of tumoricidal cytokines such as interferon-(IFN-) [5] [6] [7] , although a majority of the expanding cells will subsequently be deleted by the induction of apoptosis, and the remaining CD4 + T cells will become anergic upon subsequent exposure to the SAg [8] [9] [10] .
DC are specialized APC, which exist in virtually every tissue, capture antigens in situ, and migrate to lymphoid organs to activate naive T cells. DC are able to bind to much higher levels of SAg than other APC, and very small numbers of superantigen-MHC class II complexes are suYcient to trigger resting primary T cells [11, 12] . Recently, it became apparent that CD8 + T cells can also activate DC and support type-1 immunity as well as CD4 + T cells [13] [14] [15] . This "helper" function of CD8 + T cells depends on their ability to produce IFN-and to promote the dendritic cell production of interleukin-12 (IL-12) p70, the key factor supporting T helper 1 responses and CTL responses [16] .
DC-based tumor vaccines have demonstrated eVective antitumor immune responses in vitro and after adoptive transfer in mice and humans. However, diYculties still remain to be overcome when they are used clinically [17, 18] . We evaluated the capacity of SAg to enhance DC vaccines in the setting of some tumors including poorly immunogenic B16 melanoma. We demonstrate here that simultaneous pulsing of DC with SAg and tumor antigen results in pronounced enhancement of vaccine-mediated immune priming. Furthermore, tumor antigen and SAgpulsed DC are capable of signiWcantly suppressing the growth of established tumors and inducing a strong antitumor T-cell response after pretreatment with cyclophosphamide (CY) in a therapeutic setting [19] .
Materials and methods

Mice
Six to 8-week-old male C57BL/6 mice purchased from Japan SLC, Inc. and C57BL/6-IL12 tmljm (p40-knockout) mice purchased from the Jackson Laboratory were maintained in microisolator cages and used for all experiments at 8-10 weeks of age. All experimental procedures were approved by our institutional Animal Care and Use Committee.
Cell line, cell isolation, and culture Lewis Lung Carcinoma cells (2LL), EG7 [ovalbumin(OVA)-expressing EL4] murine lymphoma, B16-F10 murine melanoma, and J774 cells were purchased from the American Type Culture Collection. Spleen CD8 + T cells were negatively selected using MACS columns (Miltenyi Biotech) with 90% to 95% purity. L CD40L cells expressing CD40L on their cell surface and derived from murine Langerhans cells were kindly provided by Dr. Seo (Hamamatsu University, Japan) [20] . All cells were maintained in RPMI 1640 with 10% heat-inactivated fetal bovine serum (Invitrogen), glutamine, streptomycin, and penicillin (Invitrogen).
Superantigens
SEA and SEB were purchased from Toxin Technology. Naïve splenocytes from C57BL/6 mice were co-cultured with SEA or SEB or both for 3 days. The IFN-concentrations of the supernatants were determined by ELISA.
Dendritic cells
Bone marrow-derived dendritic cells (DC) were generated in cultures supplemented with granulocyte macrophage colony-stimulating factor and IL-4 (both 1,000 units/ml; R&D Systems), as described in our previous reports [21] [22] [23] . On day 7, CD11c + DC were isolated using anti-mouse CD11c-coated magnetic beads (Miltenyi Biotech) and were treated with lipopolysaccharide (250 ng/ml; Sigma-Aldrich) for 16 h. Then, the DC were collected and prepared for immunization.
Induction of IL-12p70
Antigen-free or SEA or SEB (SAg)-pulsed DC (2 £ 10 4 / 0.2 ml per well) were Wrst co-cultured for 48 h with CD8 + T cells (3 £ 10 5 from the spleens of wild-type mice), harvested, washed, counted, and stimulated (at 2 £ 10 4 /0.2 ml) with 5 £ 10 4 CD40L-transfected L cells [22] for 24 h. The IL-12p70 concentrations of the supernatant Xuid were determined by ELISA (R&D systems).
Tumor vaccines
To prepare the vaccine against EG7, after treatment with lipopolysaccharide (LPS), the DC were resuspended in RPMI 1640 and pulsed with the dominant H-2Kb-restricted ovalbumin (OVA) epitope, OVA 257-264 (SIINFEKL; synthesized by Invitrogen), alone or in combination with SAg or remained untreated (none). To prepare the B16-F10 vaccine, tyrosinase-related protein 2 (TRP-2) 180-188 (SVYDFFVWL; synthesized by Invitrogen) was used as a CTL-epitope instead of OVA [257] [258] [259] [260] [261] [262] [263] [264] . Pulsing with OVA 257-264 and TRP-2 180-188 was performed at a concentration of 10 g/ml for 60 min. To prepare the 2LL vaccine, DC were loaded overnight with 2LL tumor cells lysates (freezethawed thrice, centrifuged, and supernatant collected), at a concentration of three tumor cell equivalents to one DC, in the presence of LPS. The SAg pulsing was performed at a concentration of 1 g/ml for 60 min. The expression of CD11c, MHC II, CD86, CD80, and CD40 was analyzed by Xow cytometry before and after the SAg pulsing. All vaccines were washed twice and suspended in PBS (1 £ 10 6 per 0.2 ml).
Induction of OVA-speciWc immune response and protective immunity against EG7 tumor LPS-treated DC were pulsed with OVA 257-264 (5 g per 1 £ 10 6 DC) in the presence or absence of SAg (1 g per 1 £ 10 6 DC, respectively) and were washed twice and resuspended in PBS (1 £ 10 6 in 0.2 ml). Wild-type C57BL/ 6 mice (12 per group) were subcutaneously vaccinated (day-28) once. Cells were then harvested from the spleens of 4 week-immunized mice (half of each group) and cultured in the presence of OVA 257-264 (10 g per well) for 3 days. The IFN-concentrations of the supernatants were determined by ELISA. The remaining 4 week-immunized mice had high numbers of EG7 cells (5 £ 10 6 /mouse) inoculated into their right Xank (day 0) in order to evaluate the protective immunity induced by the vaccine. Tumors were measured using vernier calipers every 3-4 days. Data are reported as the mean § SE of tumor area (product of the largest perpendicular diameters). Furthermore, survival was recorded as the percentage of surviving animals after tumor injection and analyzed in EG7 tumor model.
CTL activity
Fourteen days after the tumor challenge, splenocytes were harvested from two animals per group. They were restimulated in vitro (8 £ 10 6 per well) for 5 days with OVA 257-264 -pulsed syngeneic splenocytes that had been treated with 50 g/ml mitomycin C (Roche Diagnostics GmbH) beforehand (two responder cells to one stimulator cell) in the presence of 10 IU/ml recombinant human IL-2 (R&D Systems) in 24-well culture plates. After the collection of viable eVector cells, various numbers of eVector cells were co-cultured with J774 cells that had been pulsed with OVA 257-264 , which were used as the target cells in this study, (at 1 £ 10 4 cells/well) for 5 h. The cell-mediated cytotoxicity of OVA 257-264 peptide was measured using a lactate dehydrogenase (LDH) cytotoxicity detection kit (Roche Diagnostics). The LDH released into the medium was measured, and the speciWc lysis of the target cells was , or B16-F10: 1.5 £ 10 5 per mouse) (day 0). The mice were i.p inoculated with CY (1 mg/0.1 ml PBS, Sigma-Aldrich) or PBS on day 2 and s.c. vaccinated (1 £ 10 6 DC) into the same Xank on day 5. Tumor area was measured every 3-4 days. Tumor size was monitored for 14 days, and then the splenocytes from two animals per group were harvested for the CTL assay. Furthermore, survival was recorded as the percentage of surviving animals and analyzed. Survival was followed as described above in EG7 tumor model.
Flow cytometory
To determine the phenotype of cultured DCs, we stained them with phycoerythrin (PE)-or Xuorescein isothiocyanate (FITC)-conjugated monoclonal antibodies against cell surface molecules (CD11c and MHC classII; obtained from Miltenyi Biotec, CD86, CD80, and CD40; obtained from Pharmingen) and analyzed on a Xow cytometry (Beckman Coulter EPICS XL). To enumerate OVA 257-264 -speciWc CD8 + T cells, spleen cells from immunized mice were stained by PE-conjugated tetrameric H-2Kb/OVA 257-264 peptide complex (synthesized by MBL) and FITC-conjugated anti-CD8 monoclonal antibody (MBL) and analyzed on a Xow cytometry (Beckman Coulter EPICS XL). Intracellular forkhead/winged helix transcription factor (Foxp3) staining was performed according to the manufacturer's instructions. BrieXy, spleen cells from vaccinated tumor-bearing mice were Wrstly surface-labeled with FITC-conjugated anti-CD4 monoclonal antibody and allophycocyanin (APC)-conjugated anti-CD25 monoclonal antibody. Then, after Wxation and permeabilization, the cells were stained with anti-Foxp3 PE (mouse regulatory T-cell staining kit; eBioscience) and analyzed on a Xow cytometry (BD FACSAria™).
Statistical analysis
Data from multiple experiments were expressed as the mean § SEM. Statistical evaluation of the diVerences between the experimental group means was performed by the Mann-Whitney U test, and time series analyses of tumor size between the experimental groups were performed by repeated measurements of ANOVA. Survival was analyzed by log-rank test on Kaplan-Meier survival curves using JMP (SAS Institute). All tests were two-sided and performed at the 0.05 signiWcance level.
Results
Naive splenocytes strongly express IFN-in the presence of both SEA and SEB To test which SAg is able to eYciently generate IFN -producing cells in vivo, we evaluated IFN-production by spleen cells from naive mice. Upon stimulation with SEA or SEB, or both, the spleen cells stimulated with a combination of SEA and SEB produced signiWcantly higher levels of IFN-than spleen cells treated with either SEA or SEB (Fig. 1a) .
Dendritic cell activation of CD8 + T cells with SAg and their phenotype
To analyze the ability of mouse CD8 + T cells to aVect dendritic cell functions in vitro, we used the previously established model of SEA/SEB-driven stimulation of T cells from wild-type C57BL/6 mice. This model allowed us to promote the interaction of dendritic cells with high numbers of CD8 + T cells without the need for prior T-cell activation and clonal expansion. In accordance with our previous data, freshly isolated mouse CD8 + T cells primed the SEA/SEB-loaded dendritic cells for high IL-12p70 production during their subsequent interaction with CD40L-expressing L cells, which were used as CD4 + T-cell surrogates (Fig. 1b) .
Then, we examined the expression patterns of various cell surface molecules by Xow cytometry. DC pulsed with SAg (SEA and SEB) and non-pulsed DC expressed similar amounts of CD11c, MHC class II molecules, CD86, CD80, and CD40, (Fig. 1c) , indicating that pulsing SAg into DC does not aVect their phenotype.
SAg/OVA-pulsed DC vaccination generates OVA 257-264 -speciWc CTL We determined the ability of SAg-pulsed DC to induce epitope-speciWc CD8 + T cells in the spleen. Using an OVA 257-264 peptide-speciWc H-2kb tetramer, we evaluated the frequencies of tetramer-bound CD8 + T cells by Xow cytometry in the spleen cells from mice that had been immunized with SAg/OVA-pulsed DC (SAg/OVA-DC) 4 week before, and compared it with that by spleen cells from mice that had been immunized with OVA 257-264 -pulsed DC (OVA-DC), SAg-pulsed DC (SAg-DC), none-pulsed DC (con-DC) or PBS. Immunization with SAg/OVA-DC resulted in signiWcantly higher numbers of OVA 257-264 -speciWc CD8
+ cells than immunization with OVA-DC, SAg-DC, con-DC or PBS (P = 0.0157, SAg/OVA-DC vs. OVA-DC, Fig. 2a) . Furthermore, upon stimulation with OVA 257-264 peptide, the spleen cells from SAg/OVA DC-immunized mice produced signiWcantly higher levels of IFN-than spleen cells from mice immunized with OVA-DC, SAg-DC or con-DC (P=0.0200, SAg/OVA-DC vs. OVA-DC, Fig. 2a  inset) . Collectively, these data suggest that immunization with SAg/OVA-pulsed DC eYciently generates OVA 257-264 -speciWc CTL and IFN--producing cells in vivo.
Next, we determined the cytolytic activities of OVA 257-264 -speciWc CTL induced by immunization with SAg/OVApulsed DC. After in vitro restimulation of immune spleen cells with the OVA 257-264 peptide, the cells from SAg/ OVA-pulsed DC-immunized mice lysed the peptide-pulsed J774 cells more eVectively than the cells from OVA-pulsed DC-immunized mice (Fig. 2b) . The CTL activity of the spleen cells from the mice immunized with SAg-pulsed DC was similar to that of the spleen cells from the mice immunized with OVA-pulsed DC. These CTL activities correlated well with the frequencies of OVA 257-264 -speciWc tetramer-bound CD8 + T cells and the levels of OVA 257-264 -speciWc IFN- (Fig. 2a, b) . SAg/OVA-pulsed DC vaccination provides protective immunity against a subsequent challenge with an EG7 OVA 257-264 expressing tumor
To ascertain whether the immune responses induced in the mice immunized with the DC vaccines eYciently protected against tumors, the vaccinated animals were subcutaneously challenged with EG7 tumors. The suppression of tumor growth was signiWcantly higher in the mice that received SAg/OVA-pulsed DC than in the mice that had received OVA-pulsed DC, SAg-pulsed DC, or untreated control DC (P = 0.0048, SAg/OVA-DC vs. OVA-DC, Fig 2c) . Subsequently, survival analysis revealed that, although all of the mice immunized with SAg-DC, OVA-DC, or control DC died within 30 days after tumor inoculation, 80% of mice immunized with SAg/OVA-pulsed DC survived (Fig. 2d) . The diVerences in the survival curves were statistically signiWcant between SAg/OVA-pulsed DC-immunized mice and OVA-pulsed DC-immunized mice (P = 0.0101).
Critical role of dendritic cells in mediating CD8 help
Whereas the inclusion of SAg strongly enhanced the immunologic and antitumor eVects of vaccination in the animals, the heterologous help from CD8 + T cells induced by SAg was not mediated by IL-12/IL-23-deWcient dendritic cells generated from the bone marrow of p40-knockout animals (Fig. 2e, f) .
SAg enhance the therapeutic eYcacy of DC-based immunization against established tumors in combination with low-dose CY To determine the therapeutic potential of immunization with SAg/OVA-pulsed DC, we attempted to induce tumor rejection in mice with EG7 tumors. In a 5-day treatment model, B6 mice harboring EG7 were treated with SAg/ OVA-pulsed DC with or without low-dose CY. As shown in Fig. 3a and b, although we could not see any potential eVect of this vaccine in terms of the induction of OVA 257-264 -speciWc CTL or tumor size reduction, treatment with a combination of SAg/OVA-pulsed DC and low-dose CY markedly generated OVA 257-264 -speciWc CTL. Furthermore, combined treatment with SAg/OVA-pulsed DC and low-dose CY resulted in a signiWcant reduction of tumor growth (P = 0.0015; compared with mice receiving OVApulsed DC). Similar eVects were observed in other two cell line two poorly immunogenic tumors (2LL and B16, respectively) ( Fig. 3c-f) . Collectively, these Wndings demonstrated that SAg enhanced the therapeutic eYcacy of DC immunization and induced protective immunity against poorly immunogenic tumors, which was achieved in combination with the systemic administration of low-dose CY. Furthermore, survival analysis revealed that survival of mice vaccinated with SAg/OVA-pulsed DC were improved in EG7 model (Fig. 3g) . The diVerences in the survival curves were statistically signiWcant between SAg/OVApulsed DC-immunized mice with CY and OVA-pulsed DC-immunized mice with CY (P = 0.0317).
Low-dose CY support the therapeutic eVect of SAg/OVA-pulsed DC vaccine by inhibiting the increase of CD4 + CD25 + Foxp3 + cells
To ascertain the role of low-dose CY in the therapeutic model, the proportion of regulatory T cells of the splenocytes from vaccinated mice was investigated using Xow cytometry (Fig. 4a) . On day 5, after tumor inoculation, B6 mice harboring EG7 were treated with SAg/OVA-pulsed DC with or without low-dose CY. Three days after vaccination, the percentage of CD4 + CD25 + Foxp3 + cells among the total CD4 + cells in the spleen was increased in the tumor-bearing mice (P = 0.0001, Naïve vs. Tumor bearing, Fig. 4b Fig. 4b ). These Wndings suggest that inhibition of regulatory T cells by systemic administration of low-dose CY support the therapeutic eVect of SAg/OVA-pulsed DC vaccine.
Discussion
Superantigens cause intense T-cell proliferation and the production of cytokines. The predominant cytokines produced and released during superantigen activation are IL-2 and IFN- [5] [6] [7] , both of which are intimately involved in the cytokine cascade during immune responses. One of + T cells, macrophages, and NK cells so that they become cytolytic. It was also reported that the high cytolytic activity detected in vaccinated mice given SEA/SEB was predominantly due to CD8 + T cells [24] . T cells activated by superantigen promotes the maturation of DC mainly via MHC classII molecule, which contributes to induce tumor-speciWc CTLs [25] . Other cell types have been found to play roles in antitumor immunity, such as NK cells or activated eosinophils, which may be marginally involved. Thus, as various cancer patients have been shown to possess low levels of tumor-speciWc T cells, superantigens may be able to expand these small populations to produce populations that are eVective at Wghting the tumor. Furthermore, IFN--induced cell growth inhibition was accompanied by the increased production of the tumor suppressor gene products p21 and p27 [26, 27] . This suggests that the direct anticellular eVects of IFN-also contribute to the antitumor protection seen in response to vaccination followed by superantigen administration. The ability of DC to generate potent type-1 immune responses has made them highly attractive for use as cancer vaccines where cytolytic immunity is desired for the clearance of tumor cells. IL-12 enhances natural killer cell and CTL activities and plays a key role in the induction of type-1 immune responses. Numerous studies have demonstrated that the co-administration of IL-12 or genetic engineering of DC to produce high levels of IL-12 strongly enhances the antitumor eYcacy of cancer vaccines [28] [29] [30] . Recently, we found that the ability of class I restricted CD8 + T cells to coactivate and polarize DC supports the induction of type-1 responses using ovalbumin or superantigen mice model [16] . Consistent with previous studies using the OVA model, heterologous help from CD8 + T cells could not be mediated by IL-12/IL-23-deWcient dendritic cells generated from the bone marrow of p40-knockout animals in this study, suggesting that dendritic cells play a critical role in mediating CD8 help for anticancer immunity.
Superantigenic stimulation of T cells prior to their activation by vaccination may ultimately lead to the induction of anergy [9, 10] . Furthermore, tumor-speciWc anergy has been shown to be an early event in the tumor-bearing host. Although the CD4 + CD25 + T-cell number is tightly regulated in normal conditions, they accumulate in tumor-bearing hosts [31, 32] . Valzasina et al. [32] reported CD4 + CD25
¡ T-cell conversion into regulatory T cells (Treg) as the mechanism of Treg replenishment and expansion in tumor-bearing mice. Furthermore, therapeutic vaccination of the tumor-bearing host expanded both tumor-induced Treg and eVector cells, but suppression was dominat, blunting the expansion of naïve Fig. 4 CD4+CD25+Foxp3+cel ls (Treg) is increased in spleen of tumor-bearing mice, which is enhanced by SAg/OVA-DC vaccine but reduced by pretreatment with low-dose cyclophosphamide. As Fig. 3a , three days after tumor inoculation, B6 mice bearing established EG7 were treated with or without CY and followed by SAg/OVA-DC vaccine or PBS. On day 8 (3 days after vaccination), the spleens were harvested and analyzed by Xow cytometry. tumor-speciWc T cells and blocking the execution of eVector function [33] . Cyclophosphamide (CY) is an alkylating agent that is widely used in the treatment of malignancies as well as autoimmune disorders. As an immunomodulatory agent, CY increases the eYcacy of various kinds of antitumor immunotherapeutic regimens, including active or adoptive immunotherapies. The administration of low-dose CY prior to DC immunization resulted in a signiWcant increase in antitumor Th1 immune responses and a decrease in the number of CD4 + CD25 + Treg cells in the tumor-bearing host [34] . Our data demonstrate that although the eYcacy of tumor antigen and SAg-pulsed DC was abolished in a therapeutic tumor-bearing model, signiWcant antitumor eVects were observed in animals bearing various established tumors (EG7, B16, and 2LL) after lowdose CY treatment. Complete tumor eradication was observed in 30-60% of mice treated with a single injection of SAg-pulsed DC, even when a weakly immunogenic B16 or 2LL tumor was used. Consistent with previous reports [31, 32, 34] , our data also demonstrated that these eYcacy might be due to an ability of CY to control the number of Treg in tumor-bearing animals.
Few studies have utilized SAg as an immune adjuvant for anti-cancer therapy. Wirth et al. [35] investigated whether the induction of a CTL response to HLA-A2-Melan-A was improved by using rVV expressing the CTL deWned epitope alone or in combination with SAg. They showed that the anti-Melan-A response was eYciently induced but that tumor suppression was not signiWcantly enhanced by coexpression of the SAg in a tumor protective model. However, the host dendritic cells might not have worked eYciently in their model. Kominsky et al. [24] reported that the vaccination of mice with irradiated B16F10 cells followed by treatment with a combination of SEA and SEB led to signiWcant and speciWc protection against subsequent challenge with viable B16F10 cells. Here, we showed that tumor antigen and SAg-pulsed ex vivo generated dendritic cells eYciently induced antitumor immunity in therapeutic models (tumor-bearing state) as well as the prophylactic setting. Although SAg is known to cause toxicity through excessive immune responses, SAg was administered in several human clinical studies as well as animal studies, and no serious adverse events were reported [36] [37] [38] . Indeed, we observed Wve non-tumorbearing animals that were injected with the same dose of SAg-pulsed DC, and they remained alive for at least a year.
In summary, systemic immune responses, as demonstrated by CTL activity and IFN-production, were signiWcantly higher and tumor speciWc when SAg-pulsed DC were used. High cytolytic activity in association with a type-1 response may have contributed to the profound in vivo anti-tumor eVects that we observed. These results strongly suggest that treatment with SAg-pulsed DC in combination with low-dose CY should be considered in humans, in order to facilitate the development of eVective strategies for therapeutic vaccination of patients with cancer and chronic infections.
